Tags

Type your tag names separated by a space and hit enter

Therapeutic effects of granulocyte-colony stimulating factor on non-alcoholic hepatic steatosis in the rat.
Ann Hepatol 2013 Jan-Feb; 12(1):115-22AH

Abstract

BACKGROUND AND RATIONALE

Non-alcoholic hepatic steatosis refers to the accumulation of triglycerides in the liver in the absence of alcohol consumption. Granulocyte colony-stimulating factor (G-CSF) has been reported to be an effective treatment for a variety of liver diseases. We examined the possible therapeutic effects of G-CSF on non-alcoholic hepatic steatosis in rats.

MATERIAL AND METHODS

Thirty-week-old Otsuka Long Evans Tokushima Fatty (OLETF) rats received water containing 30% sucrose for 8 weeks to promote the development of non-alcoholic hepatic steatosis. After development of the model, the rats were injected with G-CSF (100 μg/kg/day) or saline for 5 days. Four weeks after this treatment, serum levels of glucose, total cholesterol (TC), triglyceride (TG), alanine aminotransferase (ALT), aspartate aminotransferase (AST) and free fatty acids (FFA) were measured. Histology was examined by hematoxylin and eosin (H-E) and periodic acid Schiff (PAS) staining, and levels of expression of hepatic lipogenic enzymes were determined by RT-PCR.

RESULTS

The G-CSF-treated rats displayed significantly fewer lipid droplets than the saline-treated rats (P < 0.01), and their levels of sterol regulatory element-binding protein (SREBP)-1c, fatty acid synthase (FAS), and acetyl-CoA carboxylase (ACC) mRNAs were also lower (P < 0.01), as were their liver weight and serum levels of TG and FFA (P < 0.05).

CONCLUSION

Our results indicate that G-CSF ameliorated non-alcoholic hepatic steatosis in the OLETF rat, and this therapeutic effect involved a reduction of SREBP-1c expression. Therefore, G-CSF deserves further study as a potential treatment for non-alcoholic hepatic steatosis.

Authors+Show Affiliations

Graduate School of Biomedical Science and Engineering, Hanyang University, Seoul, Korea.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

23293202

Citation

Song, Yi-Sun, et al. "Therapeutic Effects of Granulocyte-colony Stimulating Factor On Non-alcoholic Hepatic Steatosis in the Rat." Annals of Hepatology, vol. 12, no. 1, 2013, pp. 115-22.
Song YS, Fang CH, So BI, et al. Therapeutic effects of granulocyte-colony stimulating factor on non-alcoholic hepatic steatosis in the rat. Ann Hepatol. 2013;12(1):115-22.
Song, Y. S., Fang, C. H., So, B. I., Park, J. Y., Jun, D. W., & Kim, K. S. (2013). Therapeutic effects of granulocyte-colony stimulating factor on non-alcoholic hepatic steatosis in the rat. Annals of Hepatology, 12(1), pp. 115-22.
Song YS, et al. Therapeutic Effects of Granulocyte-colony Stimulating Factor On Non-alcoholic Hepatic Steatosis in the Rat. Ann Hepatol. 2013;12(1):115-22. PubMed PMID: 23293202.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Therapeutic effects of granulocyte-colony stimulating factor on non-alcoholic hepatic steatosis in the rat. AU - Song,Yi-Sun, AU - Fang,Cheng-Hu, AU - So,Byung-Im, AU - Park,Jun-Young, AU - Jun,Dae Won, AU - Kim,Kyung-Soo, PY - 2013/1/8/entrez PY - 2013/1/8/pubmed PY - 2013/6/12/medline SP - 115 EP - 22 JF - Annals of hepatology JO - Ann Hepatol VL - 12 IS - 1 N2 - BACKGROUND AND RATIONALE: Non-alcoholic hepatic steatosis refers to the accumulation of triglycerides in the liver in the absence of alcohol consumption. Granulocyte colony-stimulating factor (G-CSF) has been reported to be an effective treatment for a variety of liver diseases. We examined the possible therapeutic effects of G-CSF on non-alcoholic hepatic steatosis in rats. MATERIAL AND METHODS: Thirty-week-old Otsuka Long Evans Tokushima Fatty (OLETF) rats received water containing 30% sucrose for 8 weeks to promote the development of non-alcoholic hepatic steatosis. After development of the model, the rats were injected with G-CSF (100 μg/kg/day) or saline for 5 days. Four weeks after this treatment, serum levels of glucose, total cholesterol (TC), triglyceride (TG), alanine aminotransferase (ALT), aspartate aminotransferase (AST) and free fatty acids (FFA) were measured. Histology was examined by hematoxylin and eosin (H-E) and periodic acid Schiff (PAS) staining, and levels of expression of hepatic lipogenic enzymes were determined by RT-PCR. RESULTS: The G-CSF-treated rats displayed significantly fewer lipid droplets than the saline-treated rats (P < 0.01), and their levels of sterol regulatory element-binding protein (SREBP)-1c, fatty acid synthase (FAS), and acetyl-CoA carboxylase (ACC) mRNAs were also lower (P < 0.01), as were their liver weight and serum levels of TG and FFA (P < 0.05). CONCLUSION: Our results indicate that G-CSF ameliorated non-alcoholic hepatic steatosis in the OLETF rat, and this therapeutic effect involved a reduction of SREBP-1c expression. Therefore, G-CSF deserves further study as a potential treatment for non-alcoholic hepatic steatosis. SN - 1665-2681 UR - https://www.unboundmedicine.com/medline/citation/23293202/Therapeutic_effects_of_granulocyte_colony_stimulating_factor_on_non_alcoholic_hepatic_steatosis_in_the_rat_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S1665-2681(19)31393-6 DB - PRIME DP - Unbound Medicine ER -